0001415889-24-001671.txt : 20240123 0001415889-24-001671.hdr.sgml : 20240123 20240123161020 ACCESSION NUMBER: 0001415889-24-001671 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240119 FILED AS OF DATE: 20240123 DATE AS OF CHANGE: 20240123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Saad Kareem CENTRAL INDEX KEY: 0001873805 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39482 FILM NUMBER: 24552589 MAIL ADDRESS: STREET 1: C/O SEMA4 HOLDINGS CORP STREET 2: 333 LUDLOW STREET, NORTH TOWER, 8TH FL. CITY: STAMFORD STATE: CT ZIP: 06902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GeneDx Holdings Corp. CENTRAL INDEX KEY: 0001818331 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 851966622 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 8TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 617 780 8742 MAIL ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 8TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Sema4 Holdings Corp. DATE OF NAME CHANGE: 20210721 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences, Inc. DATE OF NAME CHANGE: 20200715 4 1 form4-01232024_090114.xml X0508 4 2024-01-19 0001818331 GeneDx Holdings Corp. WGS 0001873805 Saad Kareem C/O GENEDX HOLDINGS CORP. 333 LUDLOW ST, NORTH TOWER STAMFORD CT 06902 false true false false CHIEF TRANSFORMATION OFFICER 0 Class A Common Stock 2024-01-19 4 M 0 546 0 A 24660 D Class A Common Stock 2024-01-22 4 S 0 193 3.24 D 24467 D Restricted Stock Unit 2024-01-19 4 M 0 546 0 D Class A Common Stock 546 2183 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. /s/ Devin Schaffer, Attorney-in-Fact 2024-01-23